Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Interviews with the Experts: Side Effects of PNH Treatment

    Although eculizumab (Soliris®) is known to be effective in treating PNH, it has ... The most frequently reported side effects of eculizumab in the PNH randomized trial were: headache, nasopharyngitis, back ... adverse reactions occurred among 4 (9%) patients receiving eculizumab and 9 (21%) patients receiving placebo (inactive ...

    Interview last updated 08/31/2016 - 8:37am.

  2. Eculizumab

    ... Eculizumab causes the complement system , a part of your immune ...

    Drug last updated 03/24/2016 - 12:32pm.

  3. Fighting PNH with Perseverance and Spirit

    ... My hematologist and I agreed on the medication ( eculizumab , known as Soliris®) I should have. When I requested the ...

    Patient Chronicle last updated 04/26/2018 - 10:49am.

  4. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab

    ... Eculizumab is indicated for the therapy of patients with symptomatic ... to inhibition of terminal complement cascade, patients on eculizumab are susceptible to Neisseria meningitidis infections. The two ...

    Research Article last updated 02/03/2017 - 11:21am.

  5. Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study

    ... annual meeting in June focused on the effectiveness of eculizumab (Soliris®). Abstract EHA18ABSSUB-5522 Gerard Socie, ... hemoglobinuria (PNH). Clinical trials have shown that eculizumab (Soliris®) reduces rates of hemolysis , or the destruction ...

    Research Review last updated 05/02/2016 - 9:26am.

  6. A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients

    ... measures, four patients with classic PNH received eculizumab whereas four patients with PNH/BMD underwent hematopoietic stem ...

    Research Article last updated 05/02/2017 - 10:42am.

  7. Small-molecule Factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

    ... alternative pathway of complement that are treated with eculizumab , a humanized monoclonal antibody against the terminal complement component C5. Eculizumab must be administered intravenously, and moreover some patients with ...

    Research Article last updated 11/28/2016 - 11:42am.

  8. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide

    ... . Patients with PNH prior to the availability of eculizumab had a median survival of between 10 and 22 years, with ...

    Research Article last updated 03/22/2017 - 2:43pm.

  9. Doctor Helps Determine Her Own Aplastic Anemia and PNH Diagnosis

    ... diagnosis. But after my diagnosis, I was placed on eculizumab (Soliris®) in a twice-monthly regimen. Although I remain ...

    Patient Chronicle last updated 04/26/2018 - 10:36am.

  10. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

    ... Kingdom were the first to treat patients with PNH with eculizumab , and were therefore able to report on long term results. This ... high rate of blood clotting ( thrombosis ) and that eculizumab reduces the chances of this complication by a factor of about 10. ...

    Research Review last updated 05/02/2016 - 9:24am.